Enterprise Value

1.534B

Cash

310.4M

Avg Qtr Burn

N/A

Short % of Float

7.87%

Insider Ownership

6.21%

Institutional Own.

83.33%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
FIRDAPSE®(Amifampridine) Details
Lamber-Eaton myasthenic syndrome

Approved

Quarterly sales

AGAMREE® (Vamorolone) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

Approved

Quarterly sales

FIRDAPSE®(Amifampridine) Details
Autoimmune disease, Lamber-Eaton myasthenic syndrome

Approved

Quarterly sales

FIRDAPSE® (Amifampridine) Details
Autoimmune disease, Neuromuscular disease

Failed

Discontinued